A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC).
J Chemother
; 2(6): 401-4, 1990 Dec.
Article
em En
| MEDLINE
| ID: mdl-1965508
ABSTRACT
A group of 28 patients with advanced non-small cell bronchogenic carcinoma (NSCBC) entered a phase II study on cisplatin (60 mg/m2, day 1) plus etoposide 120 mg/m2, day 1 to 3), every 3 weeks, in combination with lonidamine (150 mg p.o. t.i.d. continuously from day 1). Seven out of twenty-seven (26%) evaluable patients obtained a partial remission (median duration 22 weeks, range 7-47). Although the side effects were mild, three patients stopped the therapy because of them. Median survival was 14 months, range 2-19. Further studies are necessary to clarify the role of "biochemical modulators" in NSCBC.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Broncogênico
/
Carcinoma de Células Escamosas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Limite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Chemother
Assunto da revista:
ANTINEOPLASICOS
/
TERAPIA POR MEDICAMENTOS
Ano de publicação:
1990
Tipo de documento:
Article
País de afiliação:
Itália